# RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

> **NCT00805961** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 68 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **RADIATION:** Radiation therapy
- **DRUG:** Temozolomide
- **DRUG:** Bevacizumab
- **DRUG:** Bevacizumab
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00805961
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-10
- **Final completion:** 2013-05
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-12-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00805961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00805961, "RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00805961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*